Skip to main content

Table 6 2000 Cohort/Patients on OA/RA medications who also had CVD, CVA or renal morbidity, by age and sex

From: Using clinical trial data and linked administrative health data to reduce the risk of adverse events associated with the uptake of newly released drugs by older Australians: a model process

  OA/RA drugs plus
cardiovascular
disease
Male
vs.
Female
OA/RA drugs plus
cerebrovascular
disease
Male
vs.
Female
OA/RA drugs plus
renal disease
Male
vs.
Female
Age Group Male Female % Male Female % Male Female %
65-69 356 203 64 : 36 49 32 60 : 40 32 27 54 : 46
70-74 488 303 62 : 38 77 47 62 : 38 62 29 68 : 32
75-79 445 379 54 : 46 84 83 50 : 50 76 45 63 : 37
80-84 327 327 50 : 50 78 85 48 : 52 66 54 55 : 45
85-99 244 450 35 : 65 44 87 34 : 66 71 89 44 : 56
Sub-totals 1,860 1,662   332 334   307 244  
  Patients = 3,522   Patients = 666   Patients = 551